@entity1311 ( XXXX ) in the treatment of lung cancer: the Eastern Cooperative Oncology Group experience.

@entity1 @entity137 @entity1261 @entity5 @entity1149 @entity1311 @entity900 @entity2879 @entity1431 @entity1370 @entity2359
Two phase II studies of @entity1311 involving @entity1 with advanced @entity1149 ( @entity1149 ) have been completed. The first study, conducted by the Eastern Cooperative Oncology Group (ECOG), involved 25 previously untreated @entity1 who received intravenous (i.v.) @entity1311 250 mg/m2 over 24 hours every 3 weeks. Among 24 evaluable @entity1 with @entity5 , 5 partial responses (21%) were observed, median survival was 24.1 weeks, and 1-year survival was approximately 45%. Common @entity137 included @entity1431 (66% grade 4), @entity2359 (28% grade 3), and @entity1370 (12.5% grade 3). The second trial, conducted at the M.D. Anderson @entity5 Center, yielded similar results. Twenty-seven previously untreated @entity1 with @entity5 received @entity1311 200 to 250 mg/m2 i.v. over 24 hours every 3 weeks, yielding 1 complete response and 5 partial responses (24%) in 25 evaluable @entity1 . The major @entity137 was @entity1431 . No @entity1370 was seen. For the past several years ECOG has tested several agents against previously untreated @entity1149 , and none has demonstrated a response rate greater than 10%, other than @entity1311 . Given these results, the ECOG plans to conduct a three-arm phase III study involving @entity1 with advanced @entity1149 comparing 'standard' @entity900 / @entity2879 chemotherapy to two @entity1311 -containing arms: (1) @entity1311 135 mg/m2 i.v. over 24 hours plus @entity900 75 mg/m2 i.v.; (2) @entity1311 250 mg/m2 i.v. over 24 hours plus @entity900 75 mg/m2 i.v. plus recombinant @entity1 @entity1261 .(ABSTRACT TRUNCATED AT 250 WORDS)
